HemaCare, a Charles River company, is a global leader in the supply and customization of human-derived biological products and services for biomedical research, drug discovery, and cellular therapy process development. Through our network of collection centers with access to an extensive recallable and reliable donor network, our dedicated employees provide clients with the cellular material and services they need for the development of the next generation of cell and gene therapies. HemaCare supports the industry with research use and GMP-compliant starting material derived from normal and mobilized peripheral blood, bone marrow, and cord blood and isolated primary cells from these sources. Combined with Charles River’s integrated, early-stage portfolio of discovery, safety assessment, and manufacturing support services, we provide customers comprehensive solutions from discovery through commercialization.
Cryopreserved disease-state plasma samples derived from patients with ulcerative colitis.
Cryopreserved disease-state PBMC samples derived from patients with type 2 diabetes.
HemaCare supplies CD34+ cells derived from mobilized peripheral blood, bone marrow, and cord. Stem cells are isolated by positive selection using CD34+ immunomagnetic bead separation. In addition to cryopreserved CD34+ cells, HemaCare can offer stem cells in a fresh format.
Cryopreserved disease-state PBMC samples derived from patients with rheumatoid arthritis.
Cryopreserved disease-state plasma samples derived from patients with psoriasis.
Cryopreserved disease-state plasma samples derived from patients with prostate cancer.
Cell processing and isolation can be time consuming, costly, and difficult to schedule upon arrival of fresh starting material. With HemaCare’s cell processing and cell isolation services, customers can save time and money and strictly focus on their project. Our procedures are designed to minimize product variability while ensuring reproducible results. With cell processing and isolation expertise, optimized cryopreservation protocol, standardized SOPs, stringent quality standards, and rigorous QC testing, customers can expect consistently pure, viable, and functional cells with guaranteed cell counts. Human primary cells are available in fresh or cryopreserved format.
Human primary cells are derived from normal and mobilized peripheral blood (leukopak), bone marrow, and cord; from healthy donors recruited from HemaCare's large, well-characterized reliable and recallable donor pool. Primary cells available PBMCs/mononuclear cells, stem cells, T cells, B cells, NK cells, and much more!
Cryopreserved disease-state plasma samples derived from patients with ovarian cancer.
PBMCs are purified from a leukapheresis product by a density gradient centrifugation and are available in fresh or cryopreserved format.
Research use and GMP-compliant leukopaks are available in a fresh and cryopreserved format.
High-quality leukopaks play a critical role in the discovery, development, and manufacture of life-saving therapies. Leukopaks are collected in HemaCare’s FDA-registered collection centers from IRB consented healthy human donors by leukapheresis using the Spectra Optia® following optimized and standardized protocols. Cryopreserved leukopaks are cryopreserved on site immediately following collection.
In addition to normal leukopaks, HemaCare offers mobilized leukopaks with different mobilization regimens including G-CSF, Mozobil, or a combination of the two drugs.
Custom collection and isolation is available upon request.
Cryopreserved disease-state plasma samples derived from patients with non-Hodgkins lymphoma.
Cryopreserved disease-state plasma samples derived from patients with multiple sclerosis.
Cryopreserved disease-state plasma samples derived from patients with melanoma.
Macrophages are derived from purified CD14+ monocytes. CD14+ monocytes are positively selected via immunomagnetic beads and cultured (available are M1 and M2 macrophage). The phenotyping is confirmed by morphology and the expression of specific biomarkers monitored by flow cytometry. Macrophages are available in fresh or cryopreserved format.
Cryopreserved disease-state plasma samples derived from patients with lung cancer.
HemaCare provides human T cells derived from peripheral blood collected from healthy donors recruited from HemaCare's large, well-characterized reliable and recallable donor pool. Cells are isolated and processed following optimized and standardized processes and delivered in either a fresh or cryopreserved format. Available T cells include CD3 pan T cells, CD4 helper T cells, CD8 cytotoxic T cells, gamma/delta T cells, regulatory T cells, and more! Naive and Memory T cells are also available.
HemaCare provides human immune cells and tissues derived from normal and mobilized peripheral blood, bone marrow, and cord. Starting material is collected from healthy donors recruited from HemaCare's large, well-characterized reliable and recallable donor pool. Cells are isolated and processed following optimized and standardized processes and delivered in either a fresh or cryopreserved format. Cellular material available include normal and mobilized leukopaks, mononuclear cells, T cells, B cells, NK cells, dendritic cells, and more!
Cell processing and isolation can be time consuming, costly, and difficult to schedule upon arrival of fresh starting material. With HemaCare’s cell processing and cell isolation services, customers can save time and money and strictly focus on their project. Our procedures are designed to minimize product variability while ensuring reproducible results. With cell processing and isolation expertise, optimized cryopreservation protocol, standardized SOPs, stringent quality standards, and rigorous QC testing, customers can expect consistently pure, viable, and functional cells with guaranteed cell counts. Human primary cells are available in fresh or cryopreserved format.
Human primary cells are derived from normal and mobilized peripheral blood (leukopak), bone marrow, and cord; from healthy donors recruited from HemaCare's large, well-characterized reliable and recallable donor pool. Primary cells available PBMCs/mononuclear cells, stem cells, T cells, B cells, NK cells, and much more!
Platelets are collected in HemaCare’s FDA-registered collection centers from healthy IRB consented donors. Platelets are collected using the Trima Accel® Automated Blood Collection System platelet collection protocol in an acid-citrate-dextrose (ACD) anticoagulant blood bag with the potential for a single, double, or triple unit of platelets per donor in one collection.
Pan-T cells are isolated from a leukopak via positive or negative immunomagnetic cell separation and are available in fresh or cryopreserved format.
Natural killer cells are isolated from a leukopak via positive or negative immunomagnetic cell separation and are available in fresh or cryopreserved format.
Monocytes are isolated from a leukopak by positive or negative immunomagnetic bead separation and are available in fresh or cryopreserved format.
Macrophages are derived from purified CD14+ monocytes. CD14+ monocytes are positively selected via immunomagnetic beads and cultured (available are M1 and M2 macrophage). The phenotyping is confirmed by morphology and the expression of specific biomarkers monitored by flow cytometry. Macrophages are available in fresh or cryopreserved format.
Cryopreserved disease-state plasma samples derived from patients with HIV.
Dendritic cells are derived from purified monocytes. CD14 monocytes are positively selected and are cultured. Dendritic cells are available in fresh or cryopreserved format.
CD8+ cytotoxic T cells are isolated from leukopaks by positive or negative selection using immunomagnetic cell separation and are available in fresh or cryopreserved format. Memory and Naive CD8 T cells are also available.
CD4+ helper T cells are isolated from leukopaks by either positive or negative immunomagnetic bead separation and are available in fresh or cryopreserved format. Memory and Naive CD4 T cells are also available.
CD19 B cells are isolated from a leukopak by either positive or negative immunomagnetic bead separation and are available in fresh or cryopreserved format.
Bone marrow aspiration requires a sharp eye and strong technical knowledge. With over 20 years of experience, our staff expertly performs bone marrow aspiration to maximize collection of desired cellular components. The bone marrow aspiration is performed at HemaCare’s FDA-registered collection center by our qualified clinicians from IRB-consented healthy human donors. The aspirate is drawn from the posterior iliac crest (top ridge of the back of a hip bone) using a syringe attached to the needle containing anticoagulant. Also available are cell isolated from the bone marrow, including stem cells and mononuclear cells, which can be delivered in a fresh or cryopreserved format.
Research use and GMP-compliant bone marrow aspirate is available.
Bone marrow is a rich source of stem and progenitor cells, including hematopoietic stem cells (HSC) and mesenchymal stem cells (MSC). HSCs and MSCs are capable of differentiation into a number of different cell types, therefore they are a major area of investigation in regenerative medicine for the treatment of a diverse group of diseases. Research use and GMP-compliant bone marrow is available.
Bone marrow aspiration requires a sharp eye and strong technical knowledge. With over 20 years of experience, our staff expertly performs bone marrow aspiration to maximize collection of desired cellular components. The bone marrow aspiration is performed at HemaCare’s FDA-registered collection center by our qualified clinicians from IRB-consented healthy human donors. The aspirate is drawn from the posterior iliac crest (top ridge of the back of a hip bone) using a syringe attached to the needle containing anticoagulant. Also available are cell isolated from the bone marrow, including stem cells and mononuclear cells, which can be delivered in a fresh or cryopreserved format.
Research use and GMP-compliant bone marrow aspirate is available.
Successfully advancing discoveries can be expedited with the use of high-quality starting materials. With donor management expertise and tissue and apheresis collection experience, HemaCare can provide you with the quality starting material you need to advance your research. Starting material is collected within HemaCare's FDA-registered collection center from healthy donors selected from our large, pedigreed reliable and recallable donor pool. Services also include same day cell isolation and processing of starting material into various primary cell types.
Collection services include RUO and GMP-compliant fresh and cryopreserved leukopaks, mobilized leukopaks, and RUO and GMP-compliant bone marrow aspirate.
Monocytes are isolated from a leukopak by positive or negative immunomagnetic bead separation and are available in fresh or cryopreserved format.
Cryopreserved disease-state PBMC samples derived from HIV patients.
Cryopreserved disease-state PBMC samples derived from Hepatitis C patients.
Cryopreserved disease-state PBMC samples derived from Hepatitis B patients.
Human source material, such as leukopaks (normal and mobilized), bone marrow aspirate, and cord blood are critical in research and in the development of cell-based therapies. Starting material (leukopak and bone marrow aspirate) is collected from healthy donors recruited from HemaCare's large, well-characterized reliable and recallable donor pool. Collections are performed in HemaCare's FDA-registered collection center - available for research use or GMP-compliant. Cells are isolated and processed following optimized and standardized processes and delivered in either a fresh or cryopreserved format.
Inquire about a variety of cryopreserved disease-state PBMC samples for your project.
Dendritic cells are derived from CD14 monocytes, which are isolated from a leukopak by positive selection using immunomagnetic bead separation, and cultured. Dendritic cells can be delivered in either a fresh or cryopreserved format.
HemaCare supplies CD34+ cells derived from mobilized peripheral blood, bone marrow, and cord. Stem cells are isolated by positive selection using CD34+ immunomagnetic bead separation. In addition to cryopreserved CD34+ cells, HemaCare can offer stem cells in a fresh format.
Cryopreservation services include cryopreservation of human-derived raw material (i.e. leukopaks) and isolated cells. Additionally, HemaCare can accept and process/cryopreserve clinical patient material collected offsite.
Cryopreserved disease-state plasma samples derived from patients with colorectal cancer.
HemaCare can collect patient material within our FDA-registered collection center following customer-specific protocols. Additionally, HemaCare can provide GMP processing of clinical patient material collected at HemaCare or offsite within our cleanroom environment.
HemaCare can collect patient material within our FDA-registered collection center following customer-specific protocols. Additionally, HemaCare can provide GMP processing of clinical patient material collected at HemaCare or offsite within our cleanroom environment.
Cryopreserved disease-state PBMC samples derived from CML patients.
Cryopreserved disease-state plasma samples derived from patients with chronic lymphocytic leukemia.
Cryopreserved disease-state plasma samples derived from patients with cervical cancer.
HemaCare's comprehensive portfolio of research use and GMP-compliant cellular material is play an essential role as projects progress from research to preclinical development to commercialization. HemaCare's custom services include recruitment of donors to meet specific project requirements, collection of cellular material including apheresis collections and bone marrow aspiration, cell isolation and processing, and packaging and shipment of material. All processes are optimized and standardized, and with consistent, streamlined procedures from the beginning (from research use to GMP-compliant products), partners can experience a seamless transition as projects progress from preclinical to clinical development. With over 40 years of experience, HemaCare is the global leader in providing customized human-derived material for research and the development of cellular therapies, making us the unmatched partner of choice to support our partners quest in developing the next cell-based therapy.
Cells and tissues available include:
Normal and Mobilized Leukopak (RUO, GMP compliant)
Bone Marrow Aspirate (RUO, GMP compliant)
Cord Blood
Whole, plasma, serum
Mononuclear Cells/PBMCs
Stem Cells (MSC, CD34, CD133)
T Cells, B Cells, NK Cells, Monocytes
Dendritic Cells, Macrophages
And More!
Cryopreserved disease-state plasma samples derived from patients with breast cancer.
Bone marrow mononuclear cells are isolated from bone marrow aspirate using density gradient centrifugation techniques and are available in fresh or cryopreserved format.
HemaCare provides access to a wide range of cryopreserved biospecimens available for immediate delivery. Additionally, fresh biospecimens and biofluids are available. Biospecimens and biofluids available include whole blood, plasma, serum, PBMCs, stem cells, immune cells including T cells, B cells, NK cells, and much more. Also available are source material such as fresh and cryopreserved leukopak (normal and mobilized), bone marrow aspirate, and cord blood.
HemaCare provides human primary cells and tissues derived from normal and mobilized peripheral blood, bone marrow, and cord. Starting material is collected from healthy donors recruited from HemaCare's large, well-characterized reliable and recallable donor pool. Cells are isolated and processed following optimized and standardized processes and delivered in either a fresh or cryopreserved format. Cellular material available include leukopaks, mononuclear cells, stem cells, and immune cells.
Biofluids are collected onsite at HemaCare's FDA-registered collection and include normal and mobilized leukopaks, bone marrow aspirate, whole blood, plasma, serum, and more.
Cryopreserved disease-state PBMC samples derived from patients with ulcerative colitis.
Whole blood is collected from IRB consented healthy human donors in HemaCare’s FDA-registered collection centers. Unless otherwise specified, whole blood is collected in a CPD collection bag and specimen samples are collected in EDTA tubes. HemaCare can collect whole blood in any commercially available collection bag or tubes with anticoagulants per your specifications.
PBMCs are purified from a leukapheresis product by a density gradient centrifugation and are available in fresh or cryopreserved format.
Cryopreserved disease-state PBMC samples derived from psoriasis patients.
Cryopreserved disease-state plasma samples derived from patients with rheumatoid arthritis.
Cord blood mononuclear cells are purified from a cord blood unit.
Whole blood is collected from IRB consented healthy human donors in HemaCare’s FDA-registered collection centers. Unless otherwise specified, whole blood is collected in a CPD collection bag and specimen samples are collected in EDTA tubes. HemaCare can collect whole blood in any commercially available collection bag or tubes with anticoagulants per your specifications.
High-quality human source material, such as leukopaks (normal and mobilized) and bone marrow aspirate are critical in research and the development of cell-based therapies - research use and GMP compliant cellular material is available). Starting material is collected from healthy donors recruited from HemaCare's large, well-characterized reliable and recallable donor pool. Collections are performed in HemaCare's FDA-registered collection center. Cells are isolated and processed following optimized and standardized processes and delivered in either a fresh or cryopreserved format.
HemaCare can collect patient material within our FDA-registered collection center following customer-specific protocols. Additionally, HemaCare can provide GMP processing of clinical patient material collected at HemaCare or offsite within our cleanroom environment.
HemaCare's comprehensive portfolio of research use and GMP-compliant cellular material is play an essential role as projects progress from research to preclinical development to commercialization. HemaCare's services include recruitment of donors to meet specific project requirements, collection of cellular material including apheresis collections and bone marrow aspiration, cell isolation and processing, and packaging and shipment of material. All processes are optimized and standardized, and with consistent, streamlined procedures from the beginning (from research use to GMP-compliant products), partners can experience a seamless transition as projects progress from preclinical to clinical development. With over 40 years of experience, HemaCare is the global leader in providing customized human-derived material for research and the development of cellular therapies, making us the unmatched partner of choice to support our partners quest in developing the next cell-based therapy.
HemaCare provides human primary cells and tissues derived from normal and mobilized peripheral blood, bone marrow, and cord. Starting material is collected from healthy donors recruited from HemaCare's large, well-characterized reliable and recallable donor pool. Biospecimens are collected following optimized and standardized procedures. Cells are isolated and processed following optimized and standardized processes and delivered in either a fresh or cryopreserved format. Cellular material available include normal and mobilized leukopaks, mononuclear cells, stem cells, and immune cells.
Cell processing and isolation can be time consuming, costly, and difficult to schedule upon arrival of fresh starting material. With HemaCare’s cell processing and cell isolation services, customers can save time and money and strictly focus on their project. Our procedures are designed to minimize product variability while ensuring reproducible results. With cell processing and isolation expertise, optimized cryopreservation protocol, standardized SOPs, stringent quality standards, and rigorous QC testing, customers can expect consistently pure, viable, and functional cells with guaranteed cell counts.
PBMCs are purified from a leukapheresis product by a density gradient centrifugation and are available in fresh or cryopreserved format.
Cryopreserved disease-state PBMC samples derived from patients with systemic lupus erythematosus.
High-quality human source material, such as leukopaks (normal and mobilized) and bone marrow aspirate are critical in research and the development of cell-based therapies - research use and GMP compliant cellular material is available). Starting material is collected from healthy donors recruited from HemaCare's large, well-characterized reliable and recallable donor pool. Collections are performed in HemaCare's FDA-registered collection center. Cells are isolated and processed following optimized and standardized processes and delivered in either a fresh or cryopreserved format.
Cryopreserved disease-state PBMC samples derived from patients with Crohns disease.
Cryopreserved disease-state PBMC samples derived from patients with celiac disease.
HemaCare provides access to a wide range of cryopreserved biospecimens available for immediate delivery. Additionally, fresh biospecimens and biofluids are available. Biospecimens and biofluids available include whole blood, plasma, serum, PBMCs, stem cells, immune cells including T cells, B cells, NK cells, and much more. Also available are source material such as fresh and cryopreserved leukopak (normal and mobilized), bone marrow aspirate , and cord blood.
"Yes I would use Hemacare to source cells for our research! I have used Hemacare many time to get primary human CD34+ cells. The material is of high quality and have rarely had issues with material quality. They are reliable source of cells for my program and are quick to respond and execute orders in a timely manner."
"Yes. I have more than two years experience to work with HemaCare Corp., and I am very happy to be one of their client. They are very organized, well arranged. It takes me very little effort to deal with my work. Highly recommended."
HemaCare has not received any endorsements.